Most Active Stocks in Pre-Market on December 19, 2025: FOLD, TQQQ, TSLL, NKE, IBIT, MSTX, NVDA, ORCL, INVH, SMR, VICI, BBAI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy FOLD?
Source: NASDAQ.COM
NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is up 80.38 points, reaching 25,099.75, with a total volume of 89,657,766 shares traded.
Active Stocks Overview: Amicus Therapeutics (FOLD) leads with a significant increase of 3.26 to $14.15, while Nike, Inc. (NKE) shows a decline of 7.68 to $57.95, representing 68.18% of its target price.
Stock Recommendations: Several stocks, including NVIDIA (NVDA) and Oracle (ORCL), are in the "buy range" according to Zacks, with NVDA's earnings forecast showing positive revisions.
Market Highlights: Other notable stocks include ProShares UltraPro QQQ (TQQQ) and Direxion Daily TSLA Bull 2X Shares (TSLL), both showing significant increases from their 52-week lows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FOLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FOLD
Wall Street analysts forecast FOLD stock price to rise
9 Analyst Rating
2 Buy
7 Hold
0 Sell
Hold
Current: 14.490
Low
12.00
Averages
14.79
High
19.00
Current: 14.490
Low
12.00
Averages
14.79
High
19.00
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CIBRA Capital Increases Stake in Amicus Therapeutics
- Increased Holdings: CIBRA Capital Ltd increased its stake in Amicus Therapeutics by 1,476,861 shares during Q1 2026, with an estimated transaction value of $21.17 million based on average pricing, indicating strong confidence in the company.
- Asset Management Impact: The transaction resulted in a $21.40 million increase in the value of CIBRA's Amicus position at quarter-end, reflecting both trading activity and share price appreciation, highlighting its growing significance in the investment portfolio.
- Ownership Proportion: Post-transaction, CIBRA Capital holds 1,687,661 shares valued at $24.40 million, representing 11.78% of its reportable AUM, which, while not in the top five holdings, still indicates a strategic investment intent.
- Market Performance: As of April 23, 2026, Amicus Therapeutics shares were priced at $14.46, achieving a total return of 103.7% over the past year, outperforming the S&P 500 by 71.43 percentage points, showcasing its strong performance in the biotechnology sector.
See More
CIBRA Capital Increases Stake in Amicus Therapeutics
- Stake Increase: CIBRA Capital increased its stake in Amicus Therapeutics by 1,476,861 shares during Q1 2026, with an estimated trade size of $21.17 million based on average quarterly pricing, demonstrating strong confidence in the biotech firm.
- AUM Impact: The transaction resulted in a 10.2% change in reportable assets under management (AUM), indicating that CIBRA's investment has become a significant component of its overall portfolio, enhancing diversification.
- Value Appreciation: By quarter-end, CIBRA's position in Amicus was valued at $24.40 million, reflecting a $21.40 million increase due to both the acquisition of new shares and appreciation in share price, highlighting positive market sentiment.
- Competitive Edge: Amicus Therapeutics focuses on therapies for rare diseases, and with its precision medicine approach and robust pipeline, CIBRA's increased stake not only strengthens its market position in biotechnology but also lays the groundwork for future growth potential.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
- Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
- Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
- Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
- Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
- Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
- Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
See More
Rice Hall James Increases Stake in Stride by 122,430 Shares
- Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
- Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
- Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
- Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
See More
BioMarin's Drug Approved by FDA for PKU Treatment
- FDA Approval: The U.S. FDA has approved BioMarin's supplemental application for Palynziq (pegvaliase-pqpz), making it the only enzyme substitution therapy approved for managing phenylketonuria (PKU) in adolescents aged 12 and older, marking a significant advancement for the company in the rare disease sector.
- Clinical Study Results: The approval is based on the Phase 3 PEGASUS study, which demonstrated statistically significant reductions in blood phenylalanine levels at Week 72 for individuals on Palynziq compared to those on diet alone, indicating the drug's effectiveness in improving patient health outcomes.
- Market Performance Analysis: BioMarin's stock is currently trading at $59.30, which is 4.5% below its 20-day simple moving average and 8.2% below its 100-day simple moving average, reflecting short-term market weakness, with shares down approximately 19% over the past 12 months.
- Analyst Ratings: Despite the challenging market environment, BioMarin's stock carries a Buy rating with an average price target of $88.80, with recent target increases from analysts like Canaccord Genuity and Bernstein, indicating confidence in the company's future potential.
See More
CIBRA Capital Increases Stake in Amicus Therapeutics
- Increased Holdings: CIBRA Capital Ltd increased its stake in Amicus Therapeutics by 1,476,861 shares during Q1 2026, with an estimated transaction value of $21.17 million based on average pricing, indicating strong confidence in the company.
- Asset Management Impact: The transaction resulted in a $21.40 million increase in the value of CIBRA's Amicus position at quarter-end, reflecting both trading activity and share price appreciation, highlighting its growing significance in the investment portfolio.
- Ownership Proportion: Post-transaction, CIBRA Capital holds 1,687,661 shares valued at $24.40 million, representing 11.78% of its reportable AUM, which, while not in the top five holdings, still indicates a strategic investment intent.
- Market Performance: As of April 23, 2026, Amicus Therapeutics shares were priced at $14.46, achieving a total return of 103.7% over the past year, outperforming the S&P 500 by 71.43 percentage points, showcasing its strong performance in the biotechnology sector.
See More
CIBRA Capital Increases Stake in Amicus Therapeutics
- Stake Increase: CIBRA Capital increased its stake in Amicus Therapeutics by 1,476,861 shares during Q1 2026, with an estimated trade size of $21.17 million based on average quarterly pricing, demonstrating strong confidence in the biotech firm.
- AUM Impact: The transaction resulted in a 10.2% change in reportable assets under management (AUM), indicating that CIBRA's investment has become a significant component of its overall portfolio, enhancing diversification.
- Value Appreciation: By quarter-end, CIBRA's position in Amicus was valued at $24.40 million, reflecting a $21.40 million increase due to both the acquisition of new shares and appreciation in share price, highlighting positive market sentiment.
- Competitive Edge: Amicus Therapeutics focuses on therapies for rare diseases, and with its precision medicine approach and robust pipeline, CIBRA's increased stake not only strengthens its market position in biotechnology but also lays the groundwork for future growth potential.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
- Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
- Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
- Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
- Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
- Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
- Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
See More
Rice Hall James Increases Stake in Stride by 122,430 Shares
- Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
- Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
- Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
- Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
See More
BioMarin's Drug Approved by FDA for PKU Treatment
- FDA Approval: The U.S. FDA has approved BioMarin's supplemental application for Palynziq (pegvaliase-pqpz), making it the only enzyme substitution therapy approved for managing phenylketonuria (PKU) in adolescents aged 12 and older, marking a significant advancement for the company in the rare disease sector.
- Clinical Study Results: The approval is based on the Phase 3 PEGASUS study, which demonstrated statistically significant reductions in blood phenylalanine levels at Week 72 for individuals on Palynziq compared to those on diet alone, indicating the drug's effectiveness in improving patient health outcomes.
- Market Performance Analysis: BioMarin's stock is currently trading at $59.30, which is 4.5% below its 20-day simple moving average and 8.2% below its 100-day simple moving average, reflecting short-term market weakness, with shares down approximately 19% over the past 12 months.
- Analyst Ratings: Despite the challenging market environment, BioMarin's stock carries a Buy rating with an average price target of $88.80, with recent target increases from analysts like Canaccord Genuity and Bernstein, indicating confidence in the company's future potential.
See More
